DOCSLIB.ORG

Alimentary Tract and Metabolism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ATCCode ATCDescription ATCDescriptionSI ATCDescriptionLat ATCDescriptionLatPostfix A ALIMENTARY TRACT AND METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL IN PRESNOVE TRACTUS DIGESTORIUS ET METABOLISMUS A01 STOMATOLOGICAL PREPARATIONS ZDRAVILA V ZOBOZDRAVSTVU STOMATOLOGICA ORUM (N/PL) A01A Stomatological preparations Zdravila v zobozdravstvu Stomatologica orum (n/pl) A01AA Caries prophylactic agents Zdravila za zaščito pred zobnim kariesom Cariei prophylactica A01AA01 sodium fluoride natrijev fluorid natrii fluoridum i (n) A01AA02 sodium monofluorophosphate natrijev monofluorofosfat natrii monofluorophosphas atis (m) A01AA03 olaflur olaflur olaflurum i (n) A01AA04 stannous fluoride kositrov(II) fluorid stannosi fluoridum A01AA30 combinations kombinacije combinationes A01AA51 sodium fluoride, combinations natrijev fluorid, kombinacije natrii fluoridum, combinationes A01AB Antiinfectives and antiseptics for local oral treatment Protimikrobne učinkovine in antiseptiki za lokalno oralno zdravljenje Antiinfectiva et antiseptica oralia topica A01AB02 hydrogen peroxide vodikov peroksid hydrogenii peroxydum i (n) A01AB03 chlorhexidine klorheksidin chlorhexidinum i (n) A01AB04 amphotericin B amfotericin B amphotericinum B i (n) A01AB05 polynoxylin polinoksilin polynoxylinum i (n) A01AB06 domiphen domifen domiphenum i (n) A01AB07 oxyquinoline oksikinolin oxyquinolinum i (n) A01AB08 neomycin neomicin neomycinum i (n) A01AB09 miconazole mikonazol miconazolum i (n) A01AB10 natamycin natamicin natamycinum i (n) A01AB11 various razne učinkovine varia medicamenta A01AB12 hexetidine heksetidin hexetidinum i (n) A01AB13 tetracycline tetraciklin tetracyclinum i (n) A01AB14 benzoxonium chloride benzoksonijev klorid benzoxonii chloridum i (n) A01AB15 tibezonium iodide tibezonijev jodid tibezonii iodidum i (n) A01AB16 mepartricin mepartricin mepartricinum i (n) A01AB17 metronidazole metronidazol metronidazolum i (n) A01AB18 clotrimazole klotrimazol clotrimazolum i (n) A01AB19 sodium perborate natrijev perborat natrii perboras atis (m) A01AB21 chlortetracycline klortetraciklin chlortetracyclinum i (n) A01AB22 doxycycline doksiciklin doxycyclinum A01AB23 minocycline minociklin minocyclinum A01AC Corticosteroids for local oral treatment Kortikosteroidi za lokalno oralno zdravljenje Corticosteroida oralia topica A01AC01 triamcinolone triamcinolon triamcinolonum i (n) A01AC02 dexamethasone deksametazon dexamethasonum i (n) A01AC03 hydrocortisone hidrokortizon hydrocortisonum i (n) A01AC54 prednisolone, combinations prednizolon, kombinacije prednisoloni combinationes A01AD Other agents for local oral treatment Druga zdravila za lokalno oralno zdravljenje Alia medicamenta oralia topica A01AD01 epinephrine adrenalin epinephrinum i (n) A01AD02 benzydamine benzidamin benzydaminum i (n) A01AD05 acetylsalicylic acid acetilsalicilna kislina acidum acetylsalicylicum i (n) A01AD06 adrenalone adrenalon adrenalonum i (n) A01AD07 amlexanox amleksanoks amlexanoxum A01AD08 becaplermin bekaplermin becaplerminum A01AD11 various razne učinkovine varia medicamenta A02 DRUGS FOR ACID RELATED DISORDERS ZDRAVILA ZA KISLINSKO POGOJENE BOLEZNI PRAEPARATA AD MORBOS ACIDO AFFECTOS MEDENDOS A02A Antacids Antacidi Antacida orum (n/pl) A02AA Magnesium compounds Magnezijeve spojine Magnesii composita orum (n/pl) A02AA01 magnesium carbonate magnezijev karbonat magnesii carbonas atis (m) A02AA02 magnesium oxide magnezijev oksid magnesii oxidum i (n) A02AA03 magnesium peroxide magnezijev peroksid magnesii peroxidum i (n) A02AA04 magnesium hydroxide magnezijev hidroksid magnesii hydroxidum i (n) A02AA05 magnesium silicate magnezijev silikat magnesii silicas atis (m) A02AA10 combinations kombinacije combinationes A02AB Aluminium compounds Aluminijeve spojine Aluminii composita orum (n/pl) A02AB01 aluminium hydroxide aluminijev hidroksid aluminii hydroxidum i (n) A02AB02 algeldrate algeldrat algeldratum i (n) A02AB03 aluminium phosphate aluminijev fosfat aluminii phosphas atis (m) A02AB04 dihydroxialumini sodium carbonate dihidroksialuminijev natrijev karbonat dihydroxialuminii et natrii carbonas atis (m) A02AB05 aluminium acetoacetate aluminijev acetoacetat aluminii acetoacetas atis (m) A02AB06 aloglutamol aloglutamol aloglutamolum i (n) A02AB07 aluminium glycinate aluminijev glicinat aluminii glycinas atis (m) A02AB10 combinations kombinacije combinationes A02AC Calcium compounds Kalcijeve spojine Calcii composita A02AC01 calcium carbonate kalcijev karbonat calcii carbonas atis (m) A02AC02 calcium silicate kalcijev silikat calcii silicas atis (m) A02AC10 combinations kombinacije combinationes A02AD Combinations and complexes of aluminium, calcium and magnesium compounds Zdravila z aluminijem, kalcijem in magnezijem Praeparata combinata cum aluminio, calcio et magnesio A02AD01 ordinary salt combinations običajne kombinacije soli combinationes salium usuales A02AD02 magaldrate magaldrat magaldratum i (n) A02AD03 almagate almagat almagatum i (n) A02AD04 hydrotalcite hidrotalcit hydrotalcitum i (n) A02AD05 almasilate almasilat almasilatum i (n) A02AF Antacids with antiflatulents Antacidi s karminativi Antacida cum carminativis A02AF01 magaldrate and antiflatulents magaldrat in karminativi magaldratum et antiflatulentia A02AF02 ordinary salt combinations and antiflatulents običajne kombinacije soli in antiflatulenti combinationes salium usuales et antiflatulentia A02AG Antacids with antispasmodics Antacidi s spazmolitiki Antacida cum spasmolyticis A02AH Antacids with sodium bicarbonate Antacidi z natrijevim hidrogenkarbonatom Antacida cum natrii hydrogencarbonate A02AX Antacids, other combinations Antacidi, druge kombinacije Antacida, aliae combinationes A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) Zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (gerb) Praeparata ad morbus ulceris neutriculi et refluxi gastroaesophagici medendos A02BA H2-receptor antagonists Antagonisti histaminskih receptorjev H2 Antagonistae histamini in receptoribus H!d!2!n! A02BA01 cimetidine cimetidin cimetidinum i (n) A02BA02 ranitidine ranitidin ranitidinum i (n) A02BA03 famotidine famotidin famotidinum i (n) A02BA04 nizatidine nizatidin nizatidinum i (n) A02BA05 niperotidine niperotidin niperotidinum i (n) A02BA06 roxatidine roksatidin roxatidinum i (n) A02BA07 ranitidine bismuth citrate ranitidin-bizmutov citrat (kompleks ranitidina in bizmutovega citrata) ranitidini et bismuthi citratis combinatio ATCCode ATCDescription ATCDescriptionSI ATCDescriptionLat ATCDescriptionLatPostfix A02BA08 lafutidine lafutidin lafutidinum A02BA51 cimetidine, combinations cimetidin, kombinacije cimetidini combinationes A02BA53 famotidine, combinations famotidin, kombinacije famotidini combinationes A02BB Prostaglandins Prostaglandini Prostaglandina orum (n/pl) A02BB01 misoprostol mizoprostol misoprostolum i (n) A02BB02 enprostil enprostil enprostilum i (n) A02BC Proton pump inhibitors Zaviralci protonske črpalke Antliae protonum inhibitores A02BC01 omeprazole omeprazol omeprazolum i (n) A02BC02 pantoprazole pantoprazol pantoprazolum i (n) A02BC03 lansoprazole lansoprazol lansoprazolum i (n) A02BC04 rabeprazole rabeprazol rabeprazolum A02BC05 esomeprazole esomeprazol esomeprazolum A02BC06 dexlansoprazole dekslansoprazol dexlansoprazolum A02BC07 dexrabeprazole deksrabeprazol dexrabeprazolum A02BC53 lansoprazole, combinations lansoprazol, kombinacije lansoprazoli combinationes A02BC54 rabeprazole, combinations rabeprazol, combinations rabeprazoli combinations A02BD Combinations for eradication of Helicobacter pylori Kombinacije učinkovin za zdravljenje okužb z bakterijo Helicobacter pylori Medicamenta combinata ad Helicobacter pylori medendum A02BD01 omeprazole, amoxicillin and metronidazole omeprazol, amoksicilin in metronidazol omeprazolum, amoxicillinum et metronidazolum A02BD02 lansoprazole, tetracycline and metronidazole lansoprazol, tetraciklin in metronidazol lansoprazolum, tetracyclinum et metronidazolum A02BD03 lansoprazole, amoxicillin and metronidazole lansoprazol, amoksicilin in metronidazol lansoprazolum, amoxicillinum et metronidazolum A02BD04 pantoprazole, amoxicillin and clarithromycin pantoprazol, amoksicilin in klaritromicin pantoprazolum, amoxicillinum et clarithromycinum A02BD05 omeprazole, amoxicillin and clarithromycin omeprazol, amoksicilin in klaritromicin omeprazolum, amoxicillinum et clarithromycinum A02BD06 esomeprazole, amoxicillin and clarithromycin esomeprazol, amoksicilin in klaritromicin esomeprazolum, amoxicillinum et clarithromycinum A02BD07 lansoprazole, amoxicillin and clarithromycin lansoprazol, amoksicilin in klaritromicin lansoprazolum, amoxicillinum et clarithromycinum A02BD08 bismuth subcitrate, tetracycline and metronidazole bizmutov subcitrat, tetraciklin in metronidazol bismuthi subcitras, tetracyclinum et metronidazolum A02BD09 lansoprazole, clarithromycin and tinidazole lansoprazol, klaritromicin in tinidazol lansoprazolum, clarithromycinum et tinidazolum A02BD10 lansoprazole, amoxicillin and levofloxacin lansoprazol, amoksicilin in levofloksacin lansoprazolum, amoxicillinum et levofloxacinum A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Druga zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) Alia praeparata ad morbos ulceris neutriculi et refluxi gastroaesophagici medendos A02BX01 carbenoxolone karbenoksolon carbenoxolonum i (n) A02BX02 sucralfate sukralfat (aluminijev saharozni sulfat) sucralfatum i (n) A02BX03 pirenzepine pirenzepin pirenzepinum i (n) A02BX04 methiosulfonium chloride metiosulfonijev klorid methiosulfonii chloridum i (n) A02BX05 bismuth subcitrate bazični bizmutov citrat bismuthi subcitras A02BX06 proglumide proglumid proglumidum i (n) A02BX07 gefarnate gefarnat gefarnatum i (n) A02BX08 sulglicotide sulglikotid sulglicotidum i (n) A02BX09 acetoxolone acetoksolon acetoxolonum i (n) A02BX10 zolimidine zolimidin zolimidinum i (n) A02BX11 troxipide troksipid troxipidum i (n) A02BX12 bismuth subnitrate bazični bizmutov nitrat bismuthi subnitras A02BX13 alginic acid alginska kislina acidum alginicum A02BX51 carbenoxolone, combinations excl.
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Safety Data Sheet

    Safety Data Sheet

    SAFETY DATA SHEET 1. Identification Product identifier TWINRIX ADULT Other means of identification Synonyms TWINRIX ADULT INJECTION 720 EL U AND 20 MCG/ML * TWINRIX SUSPENSION FOR INJECTION * TWINRIX ADULT PRE-FILLED SYRINGE * TWINRIX ERWACHSENE AMPULLE MIT 1 ML SUSPENSION * TWINRIX ERWACHSENE FERTIGSPRITZE MIT 1 ML SUSPENSION * HAB ADULT (720/20) * COMBINED HEPATITIS A/HEPATITIS B VACCINE * TWINRIX VACUNA COMBINADA ANTIHEPATITIS A Y B * TWINRIX VACUNA CONTRA LA HEPATITIS A Y B * TWINRIX ADULTO * AMBIRIX * HEPATITIS A VIRUS ANTIGEN (HM175) AND r-DNA HEPATITIS B SURFACE ANTIGEN (HBsAg) COMBINED VACCINE Recommended use Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Recommended restrictions No other uses are advised. Manufacturer/Importer/Supplier/Distributor information COMPANY NAME GlaxoSmithKline US Address: 5 Moore Drive Research Triangle Park, NC 27709 USA Telephone: +1-888-825-5249 (General Inquiries) Email: [email protected] Website: www.gsk.com EMERGENCY CONTACTS CHEMTREC EMERGENCY NUMBERS Telephone: +(1) 703 527 3887 (International) 24/7; multi-language response Contract Number: CCN9484 VERISK 3E GLOBAL INCIDENT RESPONSE Telephone: +(1) 760 476 3971 (In country) +(1) 760 476 3962 or +(1) 866 519 4752 (International) 24/7; multi-language response Contract Number: 334878 2.
  • Aluminum Phosphates

    Aluminum Phosphates

    Dr. Ralf Giskow, The Variety of Phosphates Jörg Lind, Erwin Schmidt Chemische Fabrik Budenheim KG, for Refractory and Technical D-55257 Buden- heim www.budenheim- Applications by the Example cfb.com of Aluminium Phosphates In 1669 the chemical element phos- Phase-I-content influences, for phorus was discovered by H. Brandt, example, the dissolution property of an alchemist. In 1694 Boyle made STPP in water. The choice of the the first phosphoric acid by dissolv- right phosphate can already be the ing phosphorus pentoxide (P2O5) in crucial point even with such a “sim- water. This was the start of the phos- ple“ phosphate like sodium tripoly- phorus chemistry. Since this time phosphate. phosphoric acid and its salts have a The next step into the direction firm place in chemistry and technical of complexity is a phosphate called applications. Phosphates are part of sodium hexametaphosphate (SHMP) our life and are used in a variety of in colloquial language. In fact, the ways also in industrial fields like chemical name is a mistake. The refractories, glass, ceramics, con- name sodium hexametaphosphate struction industry and for a lot of would stand for a sodium phosphate other technical purposes. with a ring structure (“meta”). But SHMP has a chaintype structure as can be proved. These melted glassy polyphosphates (SHMP) with pH-val- Fig. 1 Phosphates in Refractory phosphates are polyphosphates with ues between three and nine, most of FABUTIT 734, a modified STPP and Technical Industries different chain lengths. The average the products also in an instantised against a standard The most common and well known chain length and thus the properties quality (Fig.
  • Sodium Aluminium Phosphate, Acidic

    Sodium Aluminium Phosphate, Acidic

    SODIUM ALUMINIUM PHOSPHATE, ACIDIC Prepared at the 61st JECFA (2003) and published in the Combined Compendium of Food Additive Specifications, FAO JECFA Monographs 1 (2005). A PTWI of 2 mg/kg bw for aluminium was established at the 74th JECFA (2011). SYNONYMS SALP; INS No. 541(i) Chemical names Sodium trialuminium tetradecahydrogen octaphosphate tetrahydrate; trisodium dialuminium pentadecahydrogen octaphosphate Chemical formula NaAl3H14(PO4)8 · 4H2O Na3Al2H15(PO4)8 Formula weight NaAl3H14(PO4)8 · 4H2O: 949.88 Na3Al2H15(PO4)8: 897.82 Assay Not less than 95% of NaAl3H14(PO4)8 · 4H2O or not less than 95% of Na3Al2H15(PO4)8 DESCRIPTION White, odourless powder FUNCTIONAL USES Raising agent CHARACTERISTICS IDENTIFICATION Solubility (Vol. 4) Insoluble in water; soluble in hydrochloric acid pH (Vol. 4) Acid to litmus Test for aluminium Passes test (Vol. 4) Test a 1 in 10 solution in dilute hydrochloric acid (1 in 2) Test for sodium (Vol. 4) Passes test Test a 1 in 10 solution in dilute hydrochloric acid (1 in 2) Test for phosphate Passes test (Vol. 4) Test a 1 in 10 solution in dilute hydrochloric acid (1 in 2) PURITY Loss on ignition (Vol. 4) NaAl3H14(PO4)8 · 4H2O: 19.5 - 21% (750-800°, 2 h) Na3Al2H15(PO4)8 : 15 - 16% (750-800°, 2 h) Fluoride (Vol. 4) Not more than 25 mg/kg (Method I) Arsenic (Vol. 4) Not more than 3 mg/kg (Method II) Lead (Vol. 4) Not more than 2 mg/kg Determine using an AAS/ICP-AES technique appropriate to the specified level. The selection of sample size and method of sample preparation may be based on the principles of the methods described in Volume 4 (under “General Methods, Metallic Impurities”).
  • Aluminium Distearate, Aluminium Hydroxide Acetate, Aluminium Phosphate and Aluminium Tristearate

    Aluminium Distearate, Aluminium Hydroxide Acetate, Aluminium Phosphate and Aluminium Tristearate

    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/393/98-FINAL April 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ALUMINIUM DISTEARATE, ALUMINIUM HYDROXIDE ACETATE, ALUMINIUM PHOSPHATE AND ALUMINIUM TRISTEARATE SUMMARY REPORT 1. Aluminium is an ubiquitous element in the environment. It is present in varying concentrations in living organisms and in foods. Aluminium compounds are widely used in veterinary and human medicine. Other uses are as an analytical reagent, food additives (e.g. sodium aluminium phosphate as anticaking agent) and in cosmetic preparations (aluminium chloride). Aluminium distearate is used for thickening lubricating oils. Aluminium hydroxide acetate and phosphate are antacids with common indications in veterinary medicine: gastric hyperacidity, peptic ulcer, gastritis and reflux esophagitis. A major use of antacids in veterinary medicine is in treatment and prevention of ruminal acidosis from grain overload, adsorbent and antidiarrheal. The dosage of aluminium hydroxide is 30 g/animal in cattle and 2 g/animal in calves and foals. Gel preparations contain approximately 4% aluminium hydroxide. Aluminium potassium sulphate is used topically as a antiseptic, astringent (i.e. washes, powders, and ‘leg tighteners’ for horses (30 to 60 g/animal) and antimycotic (1% solution for dipping or spraying sheeps with dermatophilus mycotic dermatitis). In cattle it is occasionally used for stomatitis and vaginal and intrauterine therapy at doses of 30 to 500 g/animal. In human medicine, aluminium hydroxide-based preparations have a widespread use in gastroenterology as antacids (doses of about 1 g/person orally) and as phosphate binders (doses of about 0.8 g/person orally) in patients an impairment of renal function.
  • Ep 3106176 B1

    Ep 3106176 B1

    (19) TZZ¥_Z__T (11) EP 3 106 176 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/12 (2006.01) A61K 39/39 (2006.01) 11.10.2017 Bulletin 2017/41 (21) Application number: 16183076.5 (22) Date of filing: 06.12.2012 (54) ALUMINIUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES ALUMINIUMVERBINDUNGEN ZUR VERWENDUNG FÜR THERAPEUTIKA UND IMPFSTOFFE COMPOSÉS D’ALUMINIUM POUR UTILISATION DANS DES PRODUITS THÉRAPEUTIQUES ET VACCINS (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A2-2009/158284 US-A1- 2005 158 334 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • SRIVASTAVA A K ET AL: "A purified inactivated Japaneseencephalitis virus vaccine made in vero (30) Priority: 06.12.2011 EP 11192230 cells", VACCINE, vol. 19, no. 31, 14 August 2001 13.03.2012 PCT/EP2012/054387 (2001-08-14), pages 4557-4565, XP027321987, ELSEVIER LTD, GB ISSN: 0264-410X [retrieved (43) Date of publication of application: on 2001-08-14] 21.12.2016 Bulletin 2016/51 • ANONYMOUS: "Rehydragel Adjuvants. Product profile", General Chemical , 2008, pages 1-2, (60) Divisional application: XP002684848, Retrieved from the Internet: 17185526.5 URL:http://www.generalchemical.com/assets/ pdf/Rehydragel_Adjuvants_Product_Profile.p df (62) Document number(s) of the earlier application(s) in [retrieved on 2012-10-08] accordance with Art. 76 EPC: • LINDBLAD, EB: "Special feature. Aluminium 12795830.4 / 2 788 023 compoundsfor usein vaccines", IMMUNOL.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Progress Report Antacids and Peptic Ulcer-A Reappraisal

    Progress Report Antacids and Peptic Ulcer-A Reappraisal

    Gut: first published as 10.1136/gut.20.6.538 on 1 June 1979. Downloaded from Gut, 1979, 20, 538-545 Progress report Antacids and peptic ulcer-a reappraisal There is a considerable difference of opinion between clinicians on opposite sides of the Atlantic about the role of antacid therapy in peptic ulcer. As a result of Doll's work1 most clinicians in the United Kingdom have considered antacids to be of symptomatic benefit only, but without effect on the natural history of disease. In the United States, however, antacids have remained the basic medical treatment for peptic ulcer and large quantities are prescribed in intensive regimens with the belief that they accelerate ulcer healing. Such a difference of opinion usually means that the treatment in question is without any dramatic effect and objective assessment is therefore different. It is in this field that randomised, controlled trials are most helpful, indeed vital2. Carbenoxolone3 and recently the H 2-receptor antagonists4'5 have been tested in this way and found to be effective in healing peptic ulcer. We feel a review of similar work on antacids is appropriate. The use of antacids is based on the premise that gastric acid plays some part in the causation of peptic ulcer and also on the observation that symptoms are often relieved by antacid preparations. Schwarz's dictum, 'no acid-no ulcer', is still valid, though the pattern of acid secretion is different in gastric and duodenal ulcer. Hypersecretion of acid is probably a more important http://gut.bmj.com/ factor in duodenal ulcer, though several aspects of the pathophysiology remain controversial6.
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al

    (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al

    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
  • Pharmaceutical Compositions Having Cytoprotective Properties

    Pharmaceutical Compositions Having Cytoprotective Properties

    Europaisches Patentamt J European Patent Office Office europden des brevets @ Publication number: 0 220 849 B1 EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent specification : © int CI.5 : A61K 33/08, //(A61K33/08, 27.02.91 Bulletin 91/09 33:00, 31:19) @ Application number : 86307619.6 (§) Date of filing : 02.10.86 (si) Pharmaceutical compositions having cytoprotective properties. The file contains technical information (73) Proprietor: AMERICAN HOME PRODUCTS submitted after the application was filed and CORPORATION not included in this specification 685, Third Avenue New York, New York 10017 (US) (§) Priority: 08.10.85 US 785417 20.02.86 US 831756 (72) Inventor : Borella, Luis Enrique 5 Jacob Drive Lawrenceville New Jersey (US) (43) Date of publication of application : Inventor : Dijoseph, John Francis 06.05.87 Bulletin 87/19 571 Linden Avenue Woodbridge New Jersey (US) Inventor : Mir, Ghulam Nabi (45) Publication of the grant of the patent : P.O. Box 392 27.02.91 Bulletin 91/09 Buckingham Pennsylvania 18912 (US) Inventor: Reuter, Gerald Louis 23 Crescent Drive (84) Designated Contracting States : Pittsburgh New York 12901 (US) AT BE CH DE FR GB IT LI LU NL SE (74) Representative : Porter, Graham Ronald et al @ References cited : C/O John Wyeth & Brother Limited FR-A- 2 103 569 Huntercombe Lane South Taplow CHEMICAL ABSTRACTS, vol. 80, no. 26, 1st Maidenhead Berkshire, SL6 0PH (GB) July 1974, pages 193-194, no. 149115a, Colum- bus, Ohio, US; & JP-A-74 13 319 CHEMICAL ABSTRACTS, vol. 98, no. 17, 25th April 1983, page 47, no. 137460L Columbus, Ohio, US; I.
  • EUROPEAN PHARMACOPOEIA Free Access to Supportive Pharmacopoeial Texts in the Field of Vaccines for Human Use During the Coronavirus Disease (COVID-19) Pandemic

    EUROPEAN PHARMACOPOEIA Free Access to Supportive Pharmacopoeial Texts in the Field of Vaccines for Human Use During the Coronavirus Disease (COVID-19) Pandemic

    EUROPEAN PHARMACOPOEIA Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package - October 2020 Published in accordance with the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50) European Directorate Direction européenne for the Quality de la qualité of Medicines du médicament & HealthCare & soins de santé Council of Europe Strasbourg Free access to supportive pharmacopoeial texts in the field of vaccines for human use during the coronavirus disease (COVID-19) pandemic Updated package The EDQM is committed to supporting users during the coronavirus disease (COVID-19) pandemic – as well as contributing to the wider global effort to combat the virus – by openly sharing knowledge and providing access to relevant guidance/standards. To support organisations involved in the development, manufacture or testing of COVID-19 vaccines worldwide, many of which are universities and small and medium-sized enterprises, the EDQM is offeringte mporary free access to texts of the European Pharmacopoeia (Ph. Eur.) in the field of vaccines. This package includes quality standards for vaccines which developers can take into account to help build appropriate analytical control strategies for their COVID-19 candidate vaccines and ensure the quality and safety of the final product. Application of such quality requirements may ultimately help to facilitate regulatory acceptance of a subsequent marketing authorisation application. For ease of reading, a summary table listing the pharmacopoeial texts, with information regarding the vaccine types or vaccine platforms concerned (e.g. live attenuated viral vaccine, recombinant viral-vectored vaccines) is provided.
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of